The challenges of long-term treatment outcomes in adults with malignant gliomas
- PMID: 15354923
- DOI: 10.1188/04.CJON.368-376
The challenges of long-term treatment outcomes in adults with malignant gliomas
Erratum in
- Clin J Oncol Nurs. 2004 Oct;8(5):448
Abstract
Malignant gliomas are among the most devastating tumors, with survival only one to three years after diagnosis even with the best of treatments. For this reason, long-term follow-up has not been established. Patients who do survive have significant disabilities, which compromise patient and family quality of life (QOL). Side effects from a brain tumor are dependent on the location of the tumor in the brain and can cause significant cognitive, emotional, and social effects on patients and families. Surgical treatment options also are dependent on the location of the tumor in the brain, and some sites remain inoperable (e.g., brain stem, motor strip). Radiation therapy continues to remain the mainstay of treatment for this patient population. The advent of newer technologies in radiation and chemotherapy and the development of novel treatments have increased survival. As survival increases, QOL issues become more important to patients and families. Impairment, disability, and handicap are measurements of QOL used by healthcare professionals. A multitude of studies has produced evidence regarding the impact of tumor location and size on QOL, whereas other studies have demonstrated the effects that various treatment modalities have on QOL. Few studies actually have provided insight into the everyday consequences that tumors pose on patients. Understanding the significance and causes of these impairments, disabilities, and handicaps will assist oncology nurses in caring for this special population.
Similar articles
-
Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.Oncologist. 1997;2(1):59-61. Oncologist. 1997. PMID: 10388030
-
Functional outcome after low-grade astrocytoma treatment in childhood.Cancer. 2006 Jan 15;106(2):396-402. doi: 10.1002/cncr.21612. Cancer. 2006. PMID: 16353203
-
[Treatment modalities for malignant gliomas with reference to their pathophysiology].Gan To Kagaku Ryoho. 1986 Jan;13(1):11-7. Gan To Kagaku Ryoho. 1986. PMID: 3942392 Japanese.
-
[Prognostic factors in malignant gliomas].Gan To Kagaku Ryoho. 1996 Apr;23(5):643-8. Gan To Kagaku Ryoho. 1996. PMID: 8678527 Review. Japanese.
-
Biology and treatment of malignant glioma.Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10. Semin Oncol. 2000. PMID: 10866344 Review.
Cited by
-
Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.World J Clin Oncol. 2013 Nov 10;4(4):91-101. doi: 10.5306/wjco.v4.i4.91. World J Clin Oncol. 2013. PMID: 24926429 Free PMC article.
-
Medical decision-making capacity in patients with malignant glioma.Neurology. 2009 Dec 15;73(24):2086-92. doi: 10.1212/WNL.0b013e3181c67bce. Neurology. 2009. PMID: 20018637 Free PMC article.
-
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.Neoplasia. 2018 Oct;20(10):1070-1082. doi: 10.1016/j.neo.2018.08.011. Neoplasia. 2018. PMID: 30236892 Free PMC article.
-
Employment following chemoradiotherapy in glioblastoma: a prospective case series.J Cancer Surviv. 2014 Mar;8(1):108-13. doi: 10.1007/s11764-013-0311-9. Epub 2013 Nov 9. J Cancer Surviv. 2014. PMID: 24214496
-
Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study.Support Care Cancer. 2014 May;22(5):1349-62. doi: 10.1007/s00520-013-2093-z. Epub 2014 Jan 3. Support Care Cancer. 2014. PMID: 24382676 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials